PGR and breast carcinoma: An evaluation of clinical-grade FASN inhibitors devoid of CPT-I inhibitory activity should definitely clarify the mechanistic role of FASN as a therapeutic target for differentiation therapy in certain subsets of ER+/PR- breast carcinomas [38]